Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States
et al., Diabetes Therapy, doi:10.1007/s13300-021-01110-1
, Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among.., Diabetes Therapy, doi:10.1007/s13300-021-01110-1
Retrospective 9531 COVID+ diabetes patients in the USA, showing lower risk of hospitalization with existing biguanides treatment (defined as mainly metformin in the abstract and entirely metformin in the text).
|
risk of hospitalization, 10.0% lower, RR 0.90, p < 0.001, treatment 2,067 of 4,250 (48.6%), control 3,196 of 5,281 (60.5%), NNT 8.4, odds ratio converted to relative risk.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Boye et al., 18 Jul 2021, retrospective, USA, peer-reviewed, 14 authors.
Risk Factors Associated with COVID-19 Hospitalization and Mortality: A Large Claims-Based Analysis Among People with Type 2 Diabetes Mellitus in the United States
Diabetes Therapy, doi:10.1007/s13300-021-01110-1
Introduction: Diabetes has been identified as a high-risk comorbidity for COVID-19 hospitalization. We evaluated additional risk factors for COVID-19 hospitalization and in-hospital mortality in a nationwide US database. Methods: This retrospective study utilized the UnitedHealth Group Clinical Discovery Database (January 1, 2019-July 15, 2020) containing de-identified nationwide administrative claims, SARS-CoV-2 laboratory test results, and COVID-19 inpatient admissions data. Logistic regression was used to understand risk factors for hospitalization and in-hospital mortality among people with type 2 diabetes (T2D) and in the overall population. Robustness of associations was further confirmed by subgroup and sensitivity analyses in the T2D population. Results: A total of 36,364 people were identified who were either SARS-CoV-2 ? or hospitalized for COVID-19. T2D was associated with increased COVID-19-related hospitalization and mortality. Factors associated with increased hospitalization risk were largely consistent in the overall population and the T2D subgroup, including age, male sex, and these top five comorbidities: dementia, metastatic tumor, congestive heart failure, paraplegia, and metabolic disease. Biguanides (mainly metformin) were consistently associated with lower odds of hospitalization, whereas sulfonylureas and insulins were associated with greater odds of hospitalization among people with T2D. Conclusion: In this nationwide US analysis, T2D was identified as an independent risk factor for COVID-19 complications. Many factors conferred similar risk of hospitalization across both populations; however, particular diabetes medications may be markers for differential risk. The insights on comorbidities and medications may inform population health initiatives, including prevention efforts for high-risk patient populations such as those with T2D.
References
Baral, Tsampasian, Debski, Moran, Garg et al., Association between reninangiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: a systematic review and meta-analysis, JAMA Netw Open
Bode, Garrett, Messler, Glycemic characteristics and clinical outcomes of COVID-19 hospitalized in the United States, J Diabetes Sci Technol
Bornstein, Rubino, Khunti, Practical recommendations for the management of diabetes in patients with COVID-19, Lancet Diabetes Endocrinol
Cdc Covid-, 19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12, MMWR Morb Mortal Wkly Rep
Chang, Weiner, Richards, Bleich, Segal, Validating the adapted Diabetes Complications Severity Index in claims data, Am J Manag Care
Chen, Yang, Cheng, Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care
Chen, Zhou, Dong, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
Cugno, Gualtierotti, Casazza, Tafuri, Ghigliazza et al., Mortality in PATIENTS with COVID-19 on renin angiotensin system inhibitor long-term treatment: an observational study showing that things are not always as they seem, Adv Ther
Deyo, Cherkin, Ciol, Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases, J Clin Epidemiol
Drucker, Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications, Endocr Rev
Glasheen, Dong, Diabetes Complications Severity Index (DCSI)-update and ICD-10 translation, J Diabetes Complicat
Grasselli, Zangrillo, Zanella, Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy, JAMA
Hastie, Tibshirani, Friedman, The elements of statistical learning: data mining, inference, and prediction
Holman, Knighton, Kar, Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Jordan, Adab, Cheng, Covid-19: risk factors for severe disease and death, BMJ
Klabunde, Potosky, Legler, Warren, Development of a comorbidity index using physician claims data, J Clin Epidemiol
Li, Liu, Yu, Tang, Tang, Coronavirus disease 2019 (COVID-19): current status and future perspectives, Int J Antimicrob Agents
Liu, Fang, Deng, Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province, Chin Med J (Engl)
Onder, Rezza, Brusaferro, Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy, JAMA
Petrilli, Jones, Yang, Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study, BMJ
Quan, Sundararajan, Halfon, Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data, Med Care
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Seiglie, Platt, Cromer, Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19, Diabetes Care
Sharma, Ray, Sadasivam, Metformin in COVID-19: a possible role beyond diabetes, Diabetes Res Clin Pract
Singh, Singh, Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?, Diabetes Res Clin Pract
Ursini, Russo, Pellino, Metformin and autoimmunity: a ''New Deal'' of an old drug, Front Immunol
Wu, Chen, Cai, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China JAMA Intern Med
Xu, Teng, Shang, Gu, Fan et al., The effect of prior ACEI/ARB treatment on COVID-19 susceptibility and outcome: a systematic review and meta-analysis, Clin Infect Dis
Yang, Zheng, Gou, Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and metaanalysis, Int J Infect Dis
Young, Korff, Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization, Am J Manag Care
Yu, Li, Sun, Wang, Insulin treatment is associated with increased mortality in patients with COVID-19 and type 2 diabetes, Cell Metab
Zhang, Shang, Ahn, How to best protect people with diabetes from the impact of SARS-CoV-2: report of the international COVID-19 and diabetes summit, J Diabetes Sci Technol, doi:10.1177/1932296820978399
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Zhu, She, Cheng, Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes, Cell Metab
Loading..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.